Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2016

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Benjamin Besse
  • Fonction : Auteur
Melinda Charrier
  • Fonction : Auteur
Valerie Lapierre
  • Fonction : Auteur
Eric Dansin
  • Fonction : Auteur
Olivier Lantz
David Planchard
  • Fonction : Auteur
Thierry Le Chevalier
  • Fonction : Auteur
Alain Livartoski
  • Fonction : Auteur
Fabrice Barlesik
  • Fonction : Auteur
Agnes Laplanche
  • Fonction : Auteur
Stephanie Ploix
  • Fonction : Auteur
Nadege Vimond
  • Fonction : Auteur
Isabelle Peguillet
  • Fonction : Auteur
Clotilde Thery
Ludovic Lacroix
  • Fonction : Auteur
Inka Zoernig
  • Fonction : Auteur
Kavita Dhodapkar
  • Fonction : Auteur
Madhav Dhodapkar
  • Fonction : Auteur
Sophie Viaud
  • Fonction : Auteur
Jean-Charles Soria
  • Fonction : Auteur
Katrin S. Reiners
  • Fonction : Auteur
Elke Pogge Von Strandmann
  • Fonction : Auteur
Sylvie Rusakiewicz
  • Fonction : Auteur
Alexander Eggermont
  • Fonction : Auteur
Jonathan M. Pitt
  • Fonction : Auteur
Laurence Zitvogel
Nathalie Chaput

Résumé

Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN―free) in end-stage cancer, we reported that Dex exerted natural killer (NK) cell effector functions in patients. A second generation of Dex (IFN―Dex) was manufactured with the aim of boosting NK and T cell immune responses. We carried out a phase II clinical trial testing the clinical benefit of IFN―Dex loaded with MHC class I- and class II-restricted cancer antigens as maintenance immunotherapy after induction chemotherapy in patients bearing inoperable non-small cell lung cancer (NSCLC) without tumor progression. The primary endpoint was to observe at least 50% of patients with progression-free survival (PFS) at 4 mo after chemotherapy cessation. Twenty-two patients received IFN―Dex. One patient exhibited a grade three hepatotoxicity. The median time to progression was 2.2 mo and median overall survival (OS) was 15 mo. Seven patients (32%) experienced stabilization of >4 mo. The primary endpoint was not reached. An increase in NKp30-dependent NK cell functions were evidenced in a fraction of these NSCLC patients presenting with defective NKp30 expression. Importantly, MHC class II expression levels of the final IFN―Dex product correlated with expression levels of the NKp30 ligand BAG6 on Dex, and with NKp30-dependent NK functions, the latter being associated with longer progression-free survival. This phase II trial confirmed the capacity of Dex to boost the NK cell arm of antitumor immunity in patients with advanced NSCLC.

Domaines

Immunologie

Dates et versions

hal-01440237 , version 1 (19-01-2017)

Identifiants

Citer

Benjamin Besse, Melinda Charrier, Valerie Lapierre, Eric Dansin, Olivier Lantz, et al.. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology, 2016, 5 (4), ⟨10.1080/2162402X.2015.1071008⟩. ⟨hal-01440237⟩

Collections

CNRS UNIV-AMU ANR
69 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More